Evidence map›Paper›PMID 38904084›Full record

ArticleOrganic & biomolecular chemistry2024

Borylation

Marco M D Cominetti, Zoë R Goddard, Bethany R Hood, Andrew M Beekman, Maria A O'Connell, Mark Searcey

Abstract read
In one paragraph

Article in Organic & biomolecular chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Marco M D CominettiSchool of Pharmacy, University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, UK. m.searcey@uea.ac.uk.
Zoë R GoddardSchool of Pharmacy, University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, UK. m.searcey@uea.ac.uk.ORCID 0000-0002-7900-1553
Bethany R HoodSchool of Pharmacy, University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, UK. m.searcey@uea.ac.uk.
Andrew M BeekmanSchool of Pharmacy, University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, UK. m.searcey@uea.ac.uk.ORCID 0000-0002-3056-6406
Maria A O'ConnellSchool of Pharmacy, University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, UK. m.searcey@uea.ac.uk.ORCID 0000-0002-0267-0951
Mark SearceySchool of Pharmacy, University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, UK. m.searcey@uea.ac.uk.ORCID 0000-0003-2273-8949

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The synthesis of the ethyl ester analogue of the ultrapotent antitumour antibiotic seco-duocarmycin SA has been achieved in eleven linear steps from commercially available starting materials. The DSA alkylation subunit can be made in ten linear steps from the same precursor. The route involves C-H activation at the equivalent of the C7 position on indole leading to a borylated intermediate 9 that is stable enough for peptide coupling reactions but can be easily converted to the free hydroxyl analogue.

Indexed as

DuocarmycinsIndolesIridiumBoron CompoundsCatalysisMolecular StructurePyrrolesBoron CompoundsDuocarmycinsduocarmycin SAIndolesIridiumPyrroles

Identifiers

PMID38904084
PMCPMC11234497

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.